Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > BUSINESS
BUSINESS
- Merck Serono Launches Human Growth Hormone Preparation Saizen 12 mg Subcutaneous Injection
September 12, 2013
- Nichi-Iko, BioLab Tie Up on Generic Business in Thailand
September 11, 2013
- MTPC Subsidiary in Indonesia to Construct New Production Facility
September 10, 2013
- Kyowa Kirin to Establish New Research Center in Singapore, Conduct Joint Research with Local Research Institutes
September 10, 2013
- InCROM Subsidiary in Shanghai Set to Become Subsidiary of Chinese Pharma Giant, Aims for Business Expansion
September 10, 2013
- Wholesalers to Stress that Medical Institutions Will Not Have to Incur Any Losses Due to Consumption Tax Hike
September 10, 2013
- Novartis AG Takes Retraction of JIKEI Paper “Seriously”; Problems Partly Traced to “Limited Understanding” about Investigator-Led Trials
September 9, 2013
- Shionogi Launches Irtra Combination Tablets LD/HD
September 9, 2013
- Novartis Appoints Former AbbVie Exec to Lead Medical Scientific Affairs
September 6, 2013
- Otsuka Holdings President Has High Hopes for Rapid Lead Compound Discovery
September 6, 2013
- Otsuka to Buy US Biotech Firm Astex for US$886 Million
September 6, 2013
- Takeda Mulls Taking Stab at Generic Biz in Japan via ASKA
September 6, 2013
- General Logistics Companies Increasing Their Investment in Field of Drug Distribution; Opening More Specialized Warehouses
September 6, 2013
- Edoxaban Shows Non-Inferiority to Warfarin for VTE: Daiichi Sankyo
September 6, 2013
- Will Once-weekly Formulations and New Products Help GLP-1 Receptor Agonists Break Out of Their Slump?
September 6, 2013
- Teva Japan to Pursue High-Value-Added Generics, Eyes Partnerships with Japanese Companies: Chairman Krinsky
September 5, 2013
- Teva Pharma Japan Aims for the Top in Japan Generic Market by 2018: President
September 5, 2013
- Kyowa Kirin Ties Up with Ultragenyx for XLH Treatment KRN23
September 5, 2013
- ASKA to Launch Generic Biz Unit; Takeda’s Yonezawa to Take Helm
September 4, 2013
- Otsuka Paid 20 Billion Yen to Healthcare Professionals in FY2012, 5.4 Billion Yen for Information Provisioning
September 4, 2013
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…